Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$2.4 - $4.71 $66,230 - $129,977
-27,596 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$4.58 - $8.34 $112,594 - $205,030
-24,584 Reduced 47.11%
27,596 $129,000
Q3 2021

Nov 15, 2021

BUY
$8.44 - $18.35 $349,061 - $758,919
41,358 Added 382.17%
52,180 $444,000
Q2 2021

Aug 13, 2021

BUY
$16.41 - $24.71 $177,589 - $267,411
10,822 New
10,822 $178,000

About TCR2 THERAPEUTICS INC.


  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Algert Global LLC Portfolio

Follow Algert Global LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.